Rosemary Cognition Randomized Trial: What the Evidence Says

Quick Answer

Rosemary Cognition Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 narrative review, 1 research article.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• This study consolidates the evidence based on phytochemicals for cognitive enhancement, highlighting a need for more robust, methodologically sound trials to determine if these natural compounds hold promise in cognitive therapeutics, particularly for populations with cognitive impairments. [Marsh Alexander (2026); evidence level 3]
• Accordingly, this review prespecified phytochemicals that meet 3 criteria: long-standing traditional association with cognition, biological plausibility supported by preclinical evidence, and progression into human research or commercial cognitive-health formulations, includingL. [Marsh Alexander (2026); evidence level 3]
• Excessive gestational weight gain (GWG) in women who are overweight/obese is associated with an increased risk of abnormal child neurodevelopment. [Farabi Sarah S. (2026); evidence level 4]
• The purpose of the present study was to determine whether our lifestyle intervention embedded into PAT (PAT+) improved early (18-month) offspring cognition, assessed by the Bayley Scales of Infant Development, compared to the standard PAT curriculum (PAT-only). [Farabi Sarah S. (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For rosemary cognition randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Marsh Alexander (2026). The efficacy of nutritional phytochemical compounds in improving cognition. DOI: 10.1093/ijnp/pyag003. PMCID: PMC12935010. PMID: 41575193. License: https://creativecommons.org/licenses/by-nc/4.0/ https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Acces.... https://pmc.ncbi.nlm.nih.gov/articles/PMC12935010/
• Farabi Sarah S. (2026). Effect of a Pregnancy Lifestyle Intervention Embedded Into a Home Visiting Program on Child Neurodevelopment. DOI: 10.1155/jnme/5518243. PMCID: PMC13127098. PMID: 42065005. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13127098/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.